便秘和帕金森病:双样本的孟德尔随机化分析
Huaxing Li1, Guolan Su, Weilan Kang
1Department of Neurology, Guangdong Tongjiang Hospital, Foshan, Guangdong Province, China.
Medicine
|August 27, 2025
概括
这项研究使用遗传数据研究了帕金森病 (PD) 和便秘之间的因果关系. 结果表明没有显著的双向遗传关联, 挑战了便秘是PD的早期症状的想法.
科学领域:
- 神经科学
- 遗传学
- 胃肠病学
背景情况:
- 在帕金森病患者中经常观察到便秘.
- 便秘和PD之间的因果关系尚不清楚.
- 研究这种联系对于了解PD的早期表现至关重要.
研究的目的:
- 进行双向门德尔随机化研究,以评估便秘和PD之间的潜在因果关系.
- 确定便秘是否是PD的原始特征,或者PD是否影响便秘.
- 使用遗传变异来推断这些条件之间的因果关系.
主要方法:
- 采用双向孟德尔随机化研究设计.
- 与便秘相关的遗传变异来自FinnGen联盟.
- 使用全基因组关联研究的PD总结数据来分析双向关联.
主要成果:
- 在任何方向上都没有发现便秘和PD之间的统计学意义上的因果关系.
- 前期分析 (便秘对PD的影响) 显示没有显著的关联 (OR=0. 77,P=0. 097).
- 反向分析 (PD对便秘的影响) 也没有显著的因果关系 (OR=1. 00,P=0. 845).
结论:
- 在欧洲人群中,便秘和帕金森病之间没有显著的遗传关联.
- 这些发现挑战了便秘作为PD早期特征的假设.
- 需要对更大的多民族群体进行进一步的研究,并进行共变量调整.
相关概念视频
Parkinson's Disease: Treatment
377
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
377
Parkinson's Disease: Overview
703
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
703
Neural Regulation
39.9K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.9K
Drugs for Treatment of Constipation-Predominant IBS
331
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
331
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
610
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
610
Chronic Bowel Disorders: Introduction
540
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
540


